The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Neuroendocrine neoplasia (NEN) is a heterogeneous group of tumours and often represents a therapeutic challenge to clinicians. The peptides chromogranin A (CgA), chromogranin B (CgB) and cocaine- and amphetamine-regulated transcript (CART) are widely distributed throughout the neuroendocrine system....
| Publicado en: | Annals of Clinical Biochemistry Vol. 51; no. 1; pp. 8 - 22 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
Jan2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104018297&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104018297 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00045632 8NS jtl: Annals of Clinical Biochemistry issn: 00045632 maglogo: Y pubinfo: dt: Jan2014 vid: 51 iid: 1 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 104018297 2012466970 10.1177/0004563213489670 NLM23939195 104018297 ppf: 8 ppct: 14 formats: tig: atl: The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. aug: au: Bech, P R Martin, N M Ramachandran, R Bloom, S R affil: Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK. sug: subj: Protein Precursors Nerve Tissue Proteins Neuroendocrine Tumors Neuroendocrine Tumors Diagnosis Neuroendocrine Tumors Pathology Pancreas Metabolism Pancreas Pathology Prognosis Somatostatin Metabolism Tumor Markers, Biological ab: Neuroendocrine neoplasia (NEN) is a heterogeneous group of tumours and often represents a therapeutic challenge to clinicians. The peptides chromogranin A (CgA), chromogranin B (CgB) and cocaine- and amphetamine-regulated transcript (CART) are widely distributed throughout the neuroendocrine system. CgA and CgB have been used as general NEN biomarkers for many years, while CART has only recently been identified. Of these biomarkers, CgA is the most commonly used. However, circulating CgA concentrations exhibit considerable intra-individual biological variation, are altered by proton pump inhibitors (PPIs) and somatostatin analogues and are elevated in non-NEN malignancies. Therefore, interpretation of CgA results must be in the context of these confounding factors. The effects of treatment and non-NEN conditions on circulating CgB and CART concentrations are less well understood. CgB is less affected by impaired renal function and PPIs than CgA; while, circulating CART concentrations lack a diurnal variation in humans and are more reliable markers of pancreatic NEN malignancy than CgA. The utility of circulating CgA measurements in NEN prognosis, surveillance and disease recurrence has been widely investigated. However, the utility of CgB and CART in NEN management is yet to be elucidated. Further studies are needed to establish whether CgB and CART are useful alternatives to CgA. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|